Lupin's US Generics Turn Corner, Spotlight On Upcoming Launches

A recovery in the US, aided by abating pricing pressure and portfolio exits by some large players, augurs well for Indian firm Lupin, but impending new launches including levothyroxine will need to deliver to sustain US momentum.

After sustained pressure over the past few quarters, things appear set to gather pace in the US for Lupin Ltd., with its base business products reporting gains and impending launches promising further momentum, though the firm ended Q3 with a loss post exceptional items.

Some of the US bounce back, Lupin’s management indicated, has been aided by the moderation in pricing pressures and opportunities...